1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the treatment arm.
Melanoma News
What to Know About Adjuvant Immunotherapy for Stage II/III Melanoma
Adjuvant immunotherapy with anti-PD-1 agents improves relapse-free survival in patients with stage II or III melanoma. But does everyone need treatment?
Shorter Anti-PD1 Therapy Duration Not Associated With Worse Survival in Melanoma
Among patients with resected metastatic melanoma stages III and IV, a shorter treatment duration with adjuvant anti-PD1 antibodies is not associated with worse outcomes, according to study results published in the Journal of the European Academy of Dermatology and Venereology.
Dr Pavlick on RP1 Plus Nivolumab in PD-1 Inhibitor–Pretreated Melanoma
Anna C. Pavlick, BSN, MSc, DO, MBA, a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, discussed key findings from the phase 2 IGNYTE trial (NCT03767348) investigating the efficacy and safety of RP1 plus nivolumab (Opdivo) in patients with melanoma who had progressed on prior PD-1–directed therapy.